Coronavirus company news summary - Qiagen and GT Molecular partner on new SARS-CoV-2 detection solution - PHASE Scientific’s antigen test gets FDA nod for emergency use - Verdict Medical Devices
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Qiagen and GT Molecular partner on new SARS-CoV-2 detection solution – PHASE Scientific’s antigen test gets FDA nod for emergency use

11 Aug 2021

Qiagen and GT Molecular have partnered to provide a wastewater monitoring solution to lavs across the US and Canada, combining Qiagen’s sample-preparation capabilities and QIAcuity digital polymerase chain reaction (PCR) system with GT Molecular’s digital SARS-CoV-2 Wastewater Surveillance Assay. Launched this month, the solution offers results within two and a half hours.

Cardinal Health has collaborated with Abbott and Quidel to improve access to over-the-counter rapid tests for Covid-19. Through its supply network, Cardinal Health will offer Quidel’s QuickVue At-Home OTC COVID-19 Test and Abbott’s BinaxNOW COVID-19 Antigen Self-Test. These at-home tests expand Cardinal Health’s laboratory products portfolio, which enables personalised testing and surveillance programmes for workplaces, schools and hospitality venues.

PHASE Scientific International has obtained the US Food and Drug Administration’s Emergency Use Authorization for its INDICAID COVID-19 Rapid Antigen Test. Indicated for professional use, the test can qualitatively identify SARS-CoV-2 antigen using anterior nasal swab samples in point of care settings. It holds authorisation as a consumer self-test in certain regions outside of the US, including Hong Kong.